X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-12-16 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $44.09 | -1,006 | 32,908 | -3% | -$44,352 | ||||||
2025-12-17 | RGEN | Repligen Corp | Dawes Karen A | Dir | S - Sale | $161.00 | -275 | 91,821 | 0% | -$44,275 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $76.82 | -2,688 | 47,884 | -5% | -$206,484 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $76.82 | -15,394 | 937,367 | -2% | -$1,182,526 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $76.82 | -5,447 | 278,600 | -2% | -$418,423 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $76.82 | -4,847 | 141,053 | -3% | -$372,333 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $77.09 | -3,104 | 108,065 | -3% | -$239,289 | ||||||
2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $80.10 | -7,397 | 38,958 | -16% | -$592,500 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Colpman David | Dir | P - Purchase | $0.51 | +12,500 | 31,098 | +67% | +$6,375 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Makes Brigid | Dir | P - Purchase | $0.52 | +25,000 | 27,000 | >999% | +$13,000 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Mills C Randal | Pres, CEO | P - Purchase | $0.51 | +3,000 | 379,204 | +1% | +$1,530 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Ferguson Matthew | CFO | P - Purchase | $0.53 | +60,000 | 447,110 | +15% | +$31,800 | ||||||
| D | 2025-12-15 | KYTX | Kyverna Therapeutics, Inc. | Walker Karen Marie | CTO | S - Sale+OE | $12.20 | -23,998 | 22,636 | -51% | -$292,776 | |||||
| D | 2025-12-15 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $15.57 | -113,890 | 318,478 | -26% | -$1,773,267 | |||||
| M | 2025-12-16 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.31 | +1,100 | 267,966 | 0% | +$1,444 | |||||
| D | 2025-12-17 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $82.16 | -27,563 | 0 | -100% | -$2,264,480 | |||||
| DM | 2025-12-15 | NBIX | Neurocrine Biosciences Inc | Norwalk Leslie V | Dir | S - Sale+OE | $152.78 | -6,190 | 6,239 | -50% | -$945,702 | |||||
2025-12-15 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale | $81.26 | -22,946 | 128,832 | -15% | -$1,864,678 | ||||||
| D | 2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Lin Elizabeth Yeu | Chief Medical Officer | S - Sale+OE | $79.50 | -2,078 | 40,341 | -5% | -$165,201 | |||||
2025-12-16 | DTIL | Precision Biosciences Inc | Germano Geno J | Dir | P - Purchase | $4.72 | +3,000 | 23,883 | +14% | +$14,160 | ||||||
2025-12-16 | DTIL | Precision Biosciences Inc | Frankel Stanley | Dir | P - Purchase | $4.70 | +2,700 | 19,478 | +16% | +$12,690 | ||||||
2025-12-15 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.97 | +1,381 | 23,346 | +6% | +$6,864 | ||||||
| D | 2025-10-07 | SRRK | Scholar Rock Holding Corp | Akkaraju Srinivas | Dir | P - Purchase | $39.92 | +29,599 | 6,918,784 | 0% | +$1,181,634 | |||||
| D | 2025-12-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $19.79 | -21,000 | 3,732,233 | -1% | -$415,590 | |||||
2025-12-12 | CLDI | Calidi Biotherapeutics, Inc. | Camaisa Allan | Dir | S - Sale | $1.46 | -850 | 76,952 | -1% | -$1,237 | ||||||
2025-12-12 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | P - Purchase | $0.58 | +52,000 | 3,322,990 | +2% | +$30,352 | ||||||
2025-12-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $122.00 | -3,000 | 153,503 | -2% | -$366,000 | ||||||
2025-12-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $122.00 | -3,000 | 106,221 | -3% | -$366,000 | ||||||
| D | 2025-12-15 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $8.89 | -736 | 7,488 | -9% | -$6,540 | |||||
| M | 2025-12-12 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.23 | -3,143 | 136,878 | -2% | -$38,433 | |||||
2025-12-15 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale | $7.65 | -21,210 | 315,726 | -6% | -$162,257 | ||||||
2025-12-15 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $6.00 | -3,187 | 1,209,948 | 0% | -$19,122 | ||||||
| D | 2025-12-11 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale+OE | $29.49 | -23,853 | 6,856,164 | 0% | -$703,306 | |||||
2025-12-10 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $75.38 | -20,000 | 1,212,987 | -2% | -$1,507,657 | ||||||
| D | 2025-12-10 | CDTX | Cidara Therapeutics, Inc. | Ward Shane | COO, CLO | S - Sale+OE | $220.08 | -9,959 | 25,033 | -28% | -$2,191,747 | |||||
2025-12-10 | ADPT | Adaptive Biotechnologies Corp | Hershberg Robert | Dir | S - Sale | $16.00 | -22,968 | 46,722 | -33% | -$367,488 | ||||||
| M | 2025-12-10 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $91.72 | -236,588 | 685,393 | -26% | -$21,699,044 | |||||
| D | 2025-12-09 | REPL | Replimune Group, Inc. | Dhingra Kapil | Dir | S - Sale+OE | $10.40 | -3,169 | 0 | -100% | -$32,958 | |||||
2025-12-11 | KYMR | Kymera Therapeutics, Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $86.00 | +2,005,813 | 7,955,916 | +34% | +$172,499,918 | ||||||
2025-12-09 | MRNA | Moderna, Inc. | Hussain Abbas | Dir | S - Sale | $27.60 | -504 | 1,515 | -25% | -$13,910 | ||||||
2025-12-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.53 | -257 | 404,874 | 0% | -$137 | ||||||
2025-12-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $0.53 | -526 | 483,755 | 0% | -$280 | ||||||
2025-12-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.88 | -398 | 145,004 | 0% | -$13,085 | ||||||
| D | 2025-12-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.88 | -2,255 | 875,918 | 0% | -$74,140 | |||||
2025-12-08 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $32.88 | -877 | 166,912 | -1% | -$28,834 | ||||||
2025-12-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $32.88 | -230 | 65,913 | 0% | -$7,562 | ||||||
| D | 2025-12-08 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $159.65 | -4,376 | 43,405 | -9% | -$698,615 | |||||
| M | 2025-12-05 | ADVM | Adverum Biotechnologies, Inc. | Fischer Laurent | CEO, Pres, Dir | P - Purchase | $4.30 | +128,699 | 201,513 | +177% | +$553,917 | |||||
2025-12-05 | ADVM | Adverum Biotechnologies, Inc. | Soparkar Peter | COO | P - Purchase | $4.22 | +50,000 | 80,189 | +166% | +$211,000 | ||||||
| D | 2025-12-04 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Commercial Ofc Imm Med | S - Sale+OE | $16.85 | -12,604 | 296,791 | -4% | -$212,377 | |||||
| D | 2025-12-08 | KYMR | Kymera Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $89.76 | -5,000 | 0 | -100% | -$448,823 | |||||
| D | 2025-12-08 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $89.17 | -100,000 | 660,482 | -13% | -$8,917,000 | |||||
| D | 2025-12-08 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $88.67 | -49,307 | 109,992 | -31% | -$4,371,833 | |||||
2025-12-05 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $1.21 | -4,753 | 122,982 | -4% | -$5,751 | ||||||
| M | 2025-12-04 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.22 | +36,150 | 2,196,177 | +2% | +$694,850 | |||||
| M | 2025-12-04 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.22 | +36,150 | 2,196,177 | +2% | +$694,850 | |||||
| DM | 2025-12-04 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $40.26 | -31,913 | 0 | -100% | -$1,284,749 | |||||
2025-12-05 | MGX | Metagenomi, Inc. | Thomas Brian C. | Dir | S - Sale | $1.77 | -3,830 | 2,510,960 | 0% | -$6,786 | ||||||
2025-12-05 | MGX | Metagenomi, Inc. | Wein Matthew | See Remarks | S - Sale | $1.77 | -199 | 115,031 | 0% | -$353 | ||||||
2025-12-05 | MGX | Metagenomi, Inc. | Wapnick Pamela | CFO | S - Sale | $1.77 | -1,576 | 188,956 | -1% | -$2,793 | ||||||
2025-12-05 | MGX | Metagenomi, Inc. | Irish Jian | CEO | S - Sale | $1.77 | -1,602 | 563,839 | 0% | -$2,839 | ||||||
2025-12-04 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $75.00 | -10,900 | 271,108 | -4% | -$817,500 | ||||||
2025-12-04 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $75.00 | -1,500 | 194,871 | -1% | -$112,500 | ||||||
2025-12-04 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $75.01 | -40,000 | 1,232,987 | -3% | -$3,000,400 | ||||||
| D | 2025-12-04 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.63 | -40,000 | 913,839 | -4% | -$185,200 | |||||
2025-12-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $220.15 | -50,000 | 3,031,767 | -2% | -$11,007,333 | ||||||
2025-12-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $220.15 | -50,000 | 3,031,767 | -2% | -$11,007,447 | ||||||
2025-12-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $7.54 | -10,000 | 77,526 | -11% | -$75,400 | ||||||
| M | 2025-12-03 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $18.07 | -37,212 | 1,232,312 | -3% | -$672,515 | |||||
2025-12-04 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | S - Sale | $4.19 | -524,560 | 2,149,880 | -20% | -$2,200,372 | ||||||
2025-11-17 | VXRT | Vaxart, Inc. | Watson W. Mark | Dir | P - Purchase | $0.41 | +20,000 | 124,125 | +19% | +$8,185 | ||||||
| D | 2025-12-04 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $45.21 | -136,462 | 108,964 | -56% | -$6,169,788 | |||||
2025-12-04 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $5.96 | +8,389 | 81,794 | +11% | +$49,998 | ||||||
2025-12-02 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.37 | -220,000 | 6,869,863 | -3% | -$961,400 | ||||||
2025-12-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.15 | -713 | 68,777 | -1% | -$1,535 | ||||||
2025-12-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $2.15 | -5,603 | 269,087 | -2% | -$12,064 | ||||||
2025-12-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.15 | -461 | 15,908 | -3% | -$993 | ||||||
2025-12-02 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $11.13 | -10,000 | 333,576 | -3% | -$111,300 | ||||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale+OE | $5.11 | -4,932 | 32,908 | -13% | -$25,203 | |||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale+OE | $5.11 | -10,808 | 81,388 | -12% | -$55,229 | |||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale+OE | $5.11 | -4,483 | 26,660 | -14% | -$22,908 | |||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale+OE | $5.11 | -2,701 | 26,622 | -9% | -$13,802 | |||||
| D | 2025-12-03 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $152.61 | -15,000 | 120,482 | -11% | -$2,289,083 | |||||
| D | 2025-12-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $39.14 | -1,652 | 66,562 | -2% | -$64,659 | |||||
| M | 2025-12-02 | VCEL | Vericel Corp | Wotton Paul K | Dir | S - Sale | $37.90 | -5,000 | 25,602 | -16% | -$189,500 | |||||
| M | 2025-12-01 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | S - Sale | $4.19 | -574,886 | 2,620,440 | -18% | -$2,407,833 | |||||
2025-12-03 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $1.12 | -8,056 | 127,735 | -6% | -$9,019 | ||||||
2025-12-03 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.12 | -104,347 | 6,350,415 | -2% | -$116,827 | ||||||
2025-12-03 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $1.12 | -41,687 | 501,652 | -8% | -$46,673 | ||||||
2025-12-03 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Chief Bus Ofcr, Interim CFO | S - Sale | $1.12 | -37,261 | 374,309 | -9% | -$41,717 | ||||||
| DM | 2025-12-01 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale+OE | $7.21 | -161,680 | 345,476 | -32% | -$1,164,967 | |||||
2025-12-01 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Dir | S - Sale | $23.25 | -22,249 | 85,852 | -21% | -$517,189 | ||||||
2025-12-01 | IMVT | Immunovant, Inc. | Hughes Douglas J. | Dir | S - Sale | $23.24 | -15,000 | 120,773 | -11% | -$348,665 | ||||||
2025-12-01 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $5.98 | -191,854 | 13,728,924 | -1% | -$1,147,786 | ||||||
| M | 2025-12-01 | ELUT | Elutia Inc. | Ferguson Matthew | CFO | P - Purchase | $0.66 | +10,000 | 379,071 | +3% | +$6,610 | |||||
2025-11-13 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $12.65 | +315,457 | 2,160,027 | +17% | +$3,990,531 | ||||||
2025-12-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $6.00 | -22,000 | 1,188,391 | -2% | -$132,070 | ||||||
| D | 2025-11-28 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale+OE | $19.50 | -162,820 | 216,637 | -43% | -$3,174,990 | |||||
2025-11-28 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $9.00 | +2,777 | 577,872 | 0% | +$24,993 | ||||||
| D | 2025-11-28 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $151.74 | -5,970 | 44,893 | -12% | -$905,881 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |